国际肿瘤学杂志››2023,Vol. 50››Issue (11): 701-704.doi:10.3760/cma.j.cn371439-20230828-00132
• 病例报道 •上一篇
吕璐1, 孙鹏飞2(
), 崔腾璐1
收稿日期:2023-08-28修回日期:2023-10-12出版日期:2023-11-08发布日期:2024-01-11通讯作者:孙鹏飞 E-mail:ery_sunpf@lzu.edu.cn
Received:2023-08-28Revised:2023-10-12Online:2023-11-08Published:2024-01-11摘要：
转移/复发性子宫内膜癌多采取化疗为主的综合治疗，本例子宫内膜癌颈部淋巴结转移患者采取放化疗联合派安普利单抗、安罗替尼治疗取得了满意疗效。
吕璐, 孙鹏飞, 崔腾璐. 子宫内膜癌颈部淋巴结转移综合治疗1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(11): 701-704.
图1
1例子宫内膜癌颈部淋巴结转移患者治疗前后CT及放疗靶区勾画图片 A~C为放疗前颈部、锁骨上、纵隔淋巴结转移灶；D~F为外照射放疗颈部、锁骨上、纵隔淋巴结靶区勾画；G~I为同步放化疗+免疫治疗2个周期结束后1个月颈部、锁骨上、纵隔淋巴结CT图片；J~L为综合治疗结束后6个月颈部、锁骨上、纵隔淋巴结CT图片 注：患者颈部淋巴结转移综合治疗过程包括化疗2个周期、同步放化疗+免疫治疗2个周期、化疗联合免疫治疗2个周期、免疫维持治疗5个周期、免疫治疗+靶向治疗4个周期"
| [1] | 谢玲玲, 林荣春, 林仲秋. 2017 NCCN《子宫肿瘤临床实践指南》简介[J].中国实用妇科与产科杂志,2017,33(5): 480-484. DOI:10.19538/j.fk2017050112. |
| [2] | Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J].CA Cancer J Clin,2023,73(1): 17-48. DOI:10.3322/caac.21763. |
| [3] | Post CCB, Westermann AM, Bosse T, et al. PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer[J].Crit Rev Oncol Hematol,2020,152: 102973. DOI:10.1016/j.critrevonc.2020.102973. |
| [4] | Legge F, Restaino S, Leone L, et al. Clinical outcome of recurrent endometrial cancer: analysis of post-relapse survival by pattern of recurrence and secondary treatment[J].Int J Gynecol Cancer,2020,30(2): 193-200. DOI:10.1136/ijgc-2019-000822. pmid:31792085 |
| [5] | Tronconi F, Nero C, Giudice E, et al. Advanced and recurrent endometrial cancer: state of the art and future perspectives[J].Crit Rev Oncol Hematol,2022,180: 103851. DOI:10.1016/j.critrevonc. 2022.103851. |
| [6] | Miller DS, Filiaci VL, Mannel RS, et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase Ⅲ trial (NRG oncology/GOG0209)[J].J Clin Oncol,2020,38(33): 3841-3850. DOI:10.1200/JCO.20.01076. pmid:33078978 |
| [7] | National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasmsr (version 1.2024)[EB/OL]. [2023-08-10]. https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf. |
| [8] | Howitt BE, Shukla SA, Sholl LM, et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1[J].JAMA Oncol,2015,1(9): 1319-1323. DOI:10.1001/jamaoncol.2015.2151. pmid:26181000 |
| [9] | O'Malley DM, Bariani GM, Cassier PA, et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study[J].J Clin Oncol,2022,40(7): 752-761. DOI:10.1200/JCO.21.01874. |
| [10] | Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase ⅡKEYNOTE-158 study[J].J Clin Oncol,2020,38(1): 1-10. DOI:10.1200/JCO.19.02105. pmid:31682550 |
| [11] | Oaknin A, Tinker AV, Gilbert L, et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial[J].JAMA Oncol,2020,6(11): 1766-1772. DOI:10.1001/jamaoncol.2020.4515. |
| [12] | Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer[J].N Engl J Med,2023,388(23): 2159-2170. DOI:10.1056/NEJMoa2302312. |
| [13] | Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development[J].J Hematol Oncol,2018,11(1): 120. DOI:10.1186/s13045-018-0664-7. |
| [14] | Shan YL, Zhong CJ, Ni Q, et al. Anlotinib enhanced penpulimab efficacy through remodeling of tumor vascular architecture and immune microenvironment in hPD-L1/hPD-1 humanized mouse model[J].J Clin Oncol,2021,39(15 suppl): 2581. DOI:10.1200/JCO.2021.39.15_suppl.2581. |
| [15] | Makker V, Colombo N, Casado Herráez A, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer[J].N Engl J Med,2022,386(5): 437-448. DOI:10.1056/NEJMoa2108330. |
| [16] | Wei W, Ban X, Yang F, et al. Phase Ⅱ trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer[J].J Immunother Cancer,2022,10(5): e004338. DOI:10.1136/jitc-2021-004338. |
| [17] | Uno K, Yoshihara M, Tano S, et al. Proton beam therapy for the isolated recurrence of endometrial cancer in para-aortic lymph nodes: a case report[J].BMC Womens Health,2022,22(1): 375. DOI:10.1186/s12905-022-01961-1. pmid:36104694 |
| [1] | 钱晓涛, 石子宜, 胡格, 吴晓维.Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331. |
| [2] | 王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369. |
| [3] | 高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381. |
| [4] | 范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华.炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266. |
| [5] | 王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟.铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311. |
| [6] | 张文馨, 夏泠, 彭晋, 周福祥.甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315. |
| [7] | 杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇.信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216. |
| [8] | 萨蔷, 徐航程, 王佳玉.乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234. |
| [9] | 杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙.肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238. |
| [10] | 张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛.索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253. |
| [11] | 孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好.基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150. |
| [12] | 钱晓涛, 石子宜, 胡格.Ⅲ~ⅣA期食管鳞状细胞癌根治性放化疗后行免疫检查点抑制剂维持治疗的真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(3): 151-156. |
| [13] | 李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵.寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174. |
| [14] | 刘玉兰, 井海燕, 孙静, 宋伟, 沙丹.胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180. |
| [15] | 孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹.结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118. |
| 阅读次数 | ||||||
| 全文 |
|
|||||
| 摘要 |
|
|||||
